

Calibrant Biosystems Announce Gemini™ Drug Discovery and Development Presentation and Company Update at BIO2008 Annual Meeting

Calibrant Biosystems announced today that a business and technical overview will be presented at the 2008 Biotechnology Industry Organization (BIO) annual meeting. The BIO2008 meeting will take place in San Diego, California, June 17th-20th, 2008. The Company will provide updates regarding their Gemini™ proteomic technology for drug and biomarker discovery and development, as well as companion diagnostics. Calibrant has lead programs in breast, brain, and ovarian cancer. The information will be presented in a poster to be located in the Innovation Corridor, San Diego Convention Center, Upper Level, Room 23A-C:

“Gemini is a Disruptive Discovery and Development Proteomic Platform Technology”

Poster #2165

Date and Time: Thursday, June 19th, 8:00 AM – 4:00 PM Pacific Time

Calibrant Biosystems is a Gaithersburg, MD biotechnology company specializing in targeted drug discovery from clinical tissue specimens. Calibrant’s advanced Gemini(TM) discovery platform, which is compatible with both fresh and formalin-fixed archival tissues, provides the unique ability to comparatively map protein networks between different cell types within a single tissue section. With an initial focus on monoclonal antibody drug development in oncology, Calibrant is leveraging the Gemini(TM) technology for the development of first-in-class therapeutics for cancer and other major medical needs.

Contact

Dr. Michael Salgaller
Chief Operating Officer
Calibrant Biosystems
910 Clopper Road, Suite 220N
Gaithersburg, MD 20878
Voice: 301-977-7900